litlas
Log inCreate account

Roy M. Gulick

Active 1989–2024

71
Papers
17,985
Citations
54
h-index
69
i10-index

Citations

Citations per year for Roy M. Gulick1991: 4 citations1992: 3 citations1993: 10 citations1994: 1 citations1995: 1 citations1996: 1 citations1997: 8 citations1998: 66 citations1999: 95 citations2000: 92 citations2001: 72 citations2002: 74 citations2003: 65 citations2004: 62 citations2005: 80 citations2006: 80 citations2007: 79 citations2008: 98 citations2009: 132 citations2010: 100 citations2011: 127 citations2012: 89 citations2013: 78 citations2014: 49 citations2015: 76 citations2016: 85 citations2017: 59 citations2018: 79 citations2019: 348 citations2020: 996 citations2021: 890 citations2022: 507 citations2023: 252 citations2024: 387 citations2025: 157 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,469 citing papers, 32.1% of this breakdownUnited Kingdom: 484 citing papers, 6.3% of this breakdownChina: 316 citing papers, 4.1% of this breakdownItaly: 302 citing papers, 3.9% of this breakdownSpain: 295 citing papers, 3.8% of this breakdownFrance: 285 citing papers, 3.7% of this breakdownGermany: 284 citing papers, 3.7% of this breakdownCanada: 274 citing papers, 3.6% of this breakdownNetherlands: 193 citing papers, 2.5% of this breakdownSwitzerland: 192 citing papers, 2.5% of this breakdownSouth Africa: 190 citing papers, 2.5% of this breakdownAustralia: 164 citing papers, 2.1% of this breakdown
0%32.1%Other 29.2%

Institutions

Fields

  • Medicine65.6%
  • Immunology and Microbiology23%
  • Biochemistry, Genetics and Molecular Biology4.6%
  • Pharmacology, Toxicology and Pharmaceutics1.1%
  • Psychology0.8%
  • Mathematics0.8%
  • Other4.1%

Topics

  • HIV Research and Treatment12.4%
  • HIV/AIDS drug development and treatment10.5%
  • HIV/AIDS Research and Interventions9.3%
  • COVID-19 Clinical Research Studies9%
  • Long-Term Effects of COVID-194.4%
  • SARS-CoV-2 and COVID-19 Research3.8%
  • Other50.6%

Coauthors

All papers

Open in search
  1. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Authors: Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho, Robinson Cabello, Suwat Chariyalertsak, Eileen F. Dunne, Ian Frank, Jorge A. Gallardo-Cartagena, Aditya H. Gaur, Pedro Gonzáles, Trần Việt Hà, Juan Hinojosa, Esper G. Kallás, Colleen F. Kelley, Marcelo Losso, José Valdez Madruga, Keren Middelkoop, Nittaya Phanuphak, Breno Santos, Omar Sued, Javier Valencia Huamaní, Edgar T. Overton, Shobha Swaminathan, Carlos del Rı́o, Roy M. Gulick, Paul Richardson, Philip A. Sullivan, Estelle Piwowar‐Manning, Mark A. Marzinke, Craig W. Hendrix, Maoji Li, Zhe Wang, Jeanne Marrazzo, Eric S. Daar, Aida Asmelash, Todd T. Brown, Peter L. Anderson, Susan H. Eshleman, Marcus Bryan, Cheryl Blanchette, Jonathan Lucas, Christina Psaros, Steven A. Safren, Jeremy Sugarman, Hyman Scott, Joseph J. Eron, Sheldon D. Fields, Nirupama Sista, Kailazarid Gomez-Feliciano, Andrea Jennings, Ryan Kofron, Timothy H. Holtz, Katherine Shin, James F. Rooney, Kimberly Y. Smith, William Spreen, David M. Margolis, Alex R. Rinehart, Adeola Adeyeye, Myron S. Cohen, Marybeth McCauley, Beatriz Grinsztejn - New England Journal of Medicine 2021 cited by 853

  2. Combination therapy with anti-HIV-1 antibodies maintains viral suppression

    Authors: Pilar Mendoza, Henning Gruell, Lilian Nogueira, Joy A. Pai, Allison L. Butler, Katrina G. Millard, Clara Lehmann, Isabelle Suárez, Thiago Y. Oliveira, Julio C. C. Lorenzi, Yehuda Z. Cohen, Christoph Wyen, Tim Kümmerle, Theodora K. Karagounis, Ching-Lan Lu, Lisa Handl, Cecilia Unson-O’Brien, Roshni Patel, Carola Ruping, Maike Schlotz, Maggi Witmer-Pack, Irina Shimeliovich, Gisela Kremer, Eleonore Thomas, Kelly E. Seaton, Jill Horowitz, Anthony P. West, Pamela J. Björkman, Georgia D. Tomaras, Roy M. Gulick, Nico Pfeifer, Gerd Fätkenheuer, Michael S. Seaman, Florian Klein, Marina Caskey, Michel C. Nussenzweig - Nature 2018 cited by 550

  3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

    Authors: Marina Caskey, Florian Klein, Julio C. C. Lorenzi, Michael S. Seaman, Anthony P. West, Noreen Buckley, Gisela Kremer, Lilian Nogueira, Malte Braunschweig, Johannes F. Scheid, Joshua A. Horwitz, Irina Shimeliovich, Sivan Ben‐Avraham, Maggi Witmer-Pack, Martin Platten, Clara Lehmann, Leah A. Burke, Thomas Hawthorne, Robert J. Gorelick, Bruce D. Walker, Tibor Keler, Roy M. Gulick, Gerd Fätkenheuer, Sarah J. Schlesinger, Michel C. Nussenzweig - Nature 2015 cited by 783

  4. Severe Covid-19

    Authors: David Berlin, Roy M. Gulick, Fernando J. Martínez - New England Journal of Medicine 2020 cited by 1,534

  5. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

    Authors: Marina Caskey, Till Schoofs, Henning Gruell, Allison Settler, Theodora K. Karagounis, Edward F. Kreider, Ben Murrell, Nico Pfeifer, Lilian Nogueira, Thiago Y. Oliveira, Gerald H. Learn, Yehuda Z. Cohen, Clara Lehmann, Daniel Gillor, Irina Shimeliovich, Cecilia Unson-O’Brien, Daniela Weiland, Alexander Robles, Tim Kümmerle, Christoph Wyen, Rebeka Levin, Maggi Witmer-Pack, Kemal Eren, Caroline Ignacio, Szilárd Kiss, Anthony P. West, Hugo Mouquet, Barry S. Zingman, Roy M. Gulick, Tibor Keler, Pamela J. Björkman, Michael S. Seaman, Beatrice H. Hahn, Gerd Fätkenheuer, Sarah J. Schlesinger, Michel C. Nussenzweig, Florian Klein - Nature Medicine 2017 cited by 510

  6. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

    Authors: Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar‐On, Edward F. Kreider, Ching-Lan Lu, Julio C. C. Lorenzi, Anna Feldmann, Malte Braunschweig, Lilian Nogueira, Thiago Y. Oliveira, Irina Shimeliovich, Roshni Patel, Leah Burke, Yehuda Z. Cohen, Sonya Hadrigan, Allison Settler, Maggi Witmer-Pack, Anthony P. West, Boris Juelg, Tibor Keler, Thomas Hawthorne, Barry S. Zingman, Roy M. Gulick, Nico Pfeifer, Gerald H. Learn, Michael S. Seaman, Pamela J. Björkman, Florian Klein, Sarah J. Schlesinger, Bruce D. Walker, Beatrice H. Hahn, Michel C. Nussenzweig, Marina Caskey - Nature 2016 cited by 482

  7. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies

    Authors: Golnaz Namazi, Jesse Fajnzylber, Evgenia Aga, Ronald J. Bosch, Edward P. Acosta, Radwa Sharaf, Wendy Hartogensis, Jeffrey M. Jacobson, Elizabeth Connick, Paul A. Volberding, Daniel J. Skiest, David M. Margolis, Michael C. Sneller, Susan J. Little, Sara Gianella, Davey M. Smith, Daniel R. Kuritzkes, Roy M. Gulick, John W. Mellors, Vikram Mehraj, Rajesh T. Gandhi, Ronald T. Mitsuyasu, Robert T. Schooley, Keith Henry, Pablo Tebas, Steven G. Deeks, Tae‐Wook Chun, Ann C. Collier, Jean‐Pierre Routy, Frederick Hecht, Bruce D. Walker, Jonathan Z. Li - The Journal of Infectious Diseases 2018 cited by 205

  8. Clinical Characteristics of Covid-19 in New York City

    Authors: Parag Goyal, Justin J. Choi, Laura C. Pinheiro, Edward J. Schenck, Ruijun Chen, Assem Jabri, Michael J. Satlin, Thomas R. Campion, Musarrat Nahid, Joanna Bryan Ringel, Katherine L. Hoffman, Mark N. Alshak, Han A. Li, Graham T. Wehmeyer, Mangala Rajan, Evgeniya Reshetnyak, Nathaniel Hupert, Evelyn M. Horn, Fernando J. Martínez, Roy M. Gulick, Monika M. Safford - New England Journal of Medicine 2020 cited by 2,389

  9. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

    Authors: Yotam Bar‐On, Henning Gruell, Till Schoofs, Joy A. Pai, Lilian Nogueira, Allison L. Butler, Katrina G. Millard, Clara Lehmann, Isabelle Suárez, Thiago Y. Oliveira, Theodora K. Karagounis, Yehuda Z. Cohen, Christoph Wyen, Stefan Scholten, Lisa Handl, Shiraz A. Belblidia, Juan Dizon, Jörg Janne Vehreschild, Maggi Witmer-Pack, Irina Shimeliovich, Kanika Jain, Kerstin Fiddike, Kelly E. Seaton, Nicole L. Yates, Jill Horowitz, Roy M. Gulick, Nico Pfeifer, Georgia D. Tomaras, Michael S. Seaman, Gerd Fätkenheuer, Marina Caskey, Florian Klein, Michel C. Nussenzweig - Nature Medicine 2018 cited by 262

  10. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

    Authors: Stanley Evan Cooper, Joshua Rosenblatt, Roy M. Gulick - Clinical Infectious Diseases 2022 cited by 53

  11. Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117

    Authors: Yehuda Z. Cohen, Julio C. C. Lorenzi, Lisa Krassnig, John P. Barton, Leah Burke, Joy A. Pai, Ching-Lan Lu, Pilar Mendoza, Thiago Y. Oliveira, Christopher Sleckman, Katrina G. Millard, Allison L. Butler, Juan Dizon, Shiraz A. Belblidia, Maggi Witmer-Pack, Irina Shimeliovich, Roy M. Gulick, Michael S. Seaman, Mila Janković, Marina Caskey, Michel C. Nussenzweig - The Journal of Experimental Medicine 2018 cited by 117

  12. HIV treatment and prevention 2019

    Authors: Nittaya Phanuphak, Roy M. Gulick - Current Opinion in HIV and AIDS 2019 cited by 101

  13. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing Regimens

    Authors: Michael Leonard, Zinhle Cindi, Yuki Bradford, Kassem Bourgi, John R. Koethe, Megan Turner, Jamison Norwood, Beverly Woodward, Husamettin Erdem, Rebecca Basham, Paxton Baker, Peter F. Rebeiro, Timothy R. Sterling, Todd Hulgan, Eric S. Daar, Roy M. Gulick, Sharon A. Riddler, Phumla Sinxadi, Marylyn D. Ritchie, David W. Haas - Clinical Infectious Diseases 2020 cited by 52

  14. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA <500000 Copies/mL

    Authors: Babafemi Taiwo, Lu Zheng, Andrei Ștefănescu, Amesika N. Nyaku, Baiba Bezins, Carole L. Wallis, Catherine Godfrey, Paul E. Sax, Edward P. Acosta, David W. Haas, Kimberly Y. Smith, Beverly E. Sha, Cornelius Van Dam, Roy M. Gulick - Clinical Infectious Diseases 2017 cited by 96

  15. Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    Authors: Roy M. Gulick, John W. Mellors, Diane V. Havlir, Joseph J. Eron, Charles J. Gonzalez, Deborah K. McMahon, Douglas D. Richman, Fred Valentine, Leslie Jonas, Anne R. Meibohm, Emilio A. Emini, Jeffrey Chodakewitz, Paul Deutsch, Daniel Holder, William A. Schleif, Jon H. Condra - New England Journal of Medicine 1997 cited by 1,910

  16. Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Authors: Roy M. Gulick, Jacob Lalezari, James Goodrich, Nathan Clumeck, Edwin DeJesus, Andrzej Horban, Jeffrey P. Nadler, Bonaventura Clotet, Anders Karlsson, Michael Wohlfeiler, John B Montana, Mary McHale, John F. Sullivan, Caroline E. Ridgway, Steve Felstead, Michael W. Dunne, Elna van der Ryst, Howard Mayer - New England Journal of Medicine 2008 cited by 741

  17. Raltegravir: The First HIV Type 1 Integrase Inhibitor

    Authors: Charles B. Hicks, Roy M. Gulick - Clinical Infectious Diseases 2009 cited by 162

  18. Long-Acting HIV Drugs for Treatment and Prevention

    Authors: Roy M. Gulick, Charles Flexner - Annual Review of Medicine 2018 cited by 117

  19. COVID-19

    Authors: Kristen Marks, Roy M. Gulick - Annals of Internal Medicine 2023 cited by 20

  20. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

    Authors: David W. Haas, Heather J. Ribaudo, Richard B. Kim, Camlin Tierney, G. Wilkinson, Roy M. Gulick, David B. Clifford, Todd Hulgan, Catia Marzolini, Edward P. Acosta - 2004 cited by 629

  21. Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

    Authors: Roger Paredes, Christina M. Lalama, Heather J. Ribaudo, Bruce R. Schackman, Cecilia M. Shikuma, Françoise Giguel, William A. Meyer, Victoria A. Johnson, Susan A. Fiscus, Richard T. D’Aquila, Roy M. Gulick, Daniel R. Kuritzkes - The Journal of Infectious Diseases 2010 cited by 204

  22. Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals

    Authors: David B. Clifford, Scott Evans, Yijun Yang, Edward P. Acosta, Karl Goodkin, Karen T. Tashima, David M. Simpson, David Dorfman, Heather J. Ribaudo, Roy M. Gulick, for the A5097s Study Team* - Annals of Internal Medicine 2005 cited by 272

  23. Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

    Authors: Heather J. Ribaudo, David W. Haas, C. Tierney, Richard B. Kim, G. Wilkinson, Roy M. Gulick, David B. Clifford, Catia Marzolini, Courtney V. Fletcher, Karen T. Tashima, Daniel R. Kuritzkes, Edward P. Acosta - Clinical Infectious Diseases 2006 cited by 221

  24. Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank

    Authors: Shanti Narayanasamy, Lesley H. Curtis, Adrian F. Hernandez, Christopher W. Woods, M. Anthony Moody, Mark Sulkowski, Sarah E. Turbett, Lindsey R. Baden, Roy M. Gulick, Alice K. Pau, Stacey J. Adam, Peter Marks, Norman Stockbridge, John R Dobbins, Esther Krofah, Brett Leav, Phil Pang, Lothar Roessig, Ola Vedin, Joanne Waldstreicher, Stacey Cromer Berman, Henry Cremisi, Lesley Schofield, Rajesh T. Gandhi, Susanna Naggie - Clinical Infectious Diseases 2023 cited by 20